Want to see HK:1332 full AI Analyst Report?
Top Page
China Touyun Tech Group
(1332)
Select Model
Select Model
Rating:45Neutral
Price Target:
HK$0.15
▼(-30.95% Downside)
Action:Reiterated
Date:08/28/26
The score is primarily weighed down by weak financial performance (shrinking revenue, persistent operating losses, negative equity, and ongoing cash burn), which signals elevated solvency and execution risk. Technical indicators provide some near-term support (price above shorter-term moving averages and positive MACD), but overbought signals and a still-weaker longer-term trend cap the benefit. Valuation is also a headwind due to a high P/E and no dividend yield provided.
Positive Factors
Positive net income in 2025
Positive net income in 2025 is a measurable improvement in reported earnings, but the pack says it appears non-operating because EBIT and EBITDA remained deeply negative. It therefore offers limited evidence of durable profitability, yet may still provide temporary earnings support over the next few periods.
Negative Factors
Severe revenue contraction
Repeated revenue contraction, including a 42.9% decline in 2025, signals weakening demand and loss of operating scale. A smaller revenue base makes it harder to absorb fixed costs, rebuild margins, and generate sustainable earnings unless the company reverses the decline.
Read all positive and negative factors
Positive Factors
Negative Factors
Positive net income in 2025
Positive net income in 2025 is a measurable improvement in reported earnings, but the pack says it appears non-operating because EBIT and EBITDA remained deeply negative. It therefore offers limited evidence of durable profitability, yet may still provide temporary earnings support over the next few periods.
Read all positive factors
China Touyun Tech Group (1332) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$433.48M
Dividend YieldN/A
Average Volume (3M)1.13M
Price to Earnings (P/E)2.2
Beta (1Y)-0.07
Revenue Growth-39.50%
EPS GrowthN/A
CountryHK
Employees302
SectorConsumer Cyclical
Sector Strength84
IndustryPackaging & Containers
Share Statistics
EPS (TTM)0.07
Shares Outstanding2,928,952,100
10 Day Avg. Volume1,004,093
30 Day Avg. Volume1,125,500
Financial Highlights & Ratios
PEG Ratio-1.74
Price to Book (P/B)-14.01
Price to Sales (P/S)10.69
P/FCF Ratio-21.97
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
China Touyun Tech Group Business Overview & Revenue Model
Company Description
Touyun Biotech Group Limited functions as a diversified investment holding company, primarily focused on the global design, development, manufacturing, and sale of a wide array of packaging products. Its market presence extends across Hong Kong, t...
China Touyun Tech Group Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
18
Very Negative
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 70.84M | 66.97M | 159.97M | 198.64M | 315.82M | 283.50M |
| Gross Profit | 15.88M | 16.22M | 72.07M | 56.60M | 120.12M | 107.05M |
| EBITDA | -22.65M | -37.97M | -17.19M | -228.57M | -144.39M | -83.13M |
| Net Income | 213.40M | 26.80M | -88.11M | -268.94M | -198.06M | -72.95M |
Balance Sheet | ||||||
| Total Assets | 977.26M | 619.70M | 550.32M | 607.34M | 887.70M | 1.02B |
| Cash, Cash Equivalents and Short-Term Investments | 4.39M | 5.06M | 69.64M | 36.04M | 144.25M | 93.95M |
| Total Debt | 482.12M | 413.62M | 384.59M | 384.91M | 395.01M | 317.37M |
| Total Liabilities | 644.63M | 592.31M | 590.96M | 586.27M | 604.19M | 537.68M |
| Stockholders Equity | 141.19M | -51.10M | -83.20M | -848.00K | 263.96M | 469.92M |
Cash Flow | ||||||
| Free Cash Flow | -12.85M | -32.60M | -53.54M | -13.49M | -39.30M | -304.60M |
| Operating Cash Flow | -9.45M | -29.64M | -49.87M | 3.65M | -26.37M | -53.81M |
| Investing Cash Flow | -17.60M | -10.80M | -4.66M | -70.95M | -17.25M | -147.74M |
| Financing Cash Flow | 16.28M | 27.32M | 35.74M | -27.68M | 102.63M | 123.17M |
China Touyun Tech Group Technical Analysis
Negative
0.21
Price Trends
0.15
Negative
0.14
Positive
0.15
Negative
Market Momentum
>-0.01
Positive
44.30
Neutral
29.41
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1332, the sentiment is Negative. The current price of 0.21 is above the 20-day moving average (MA) of 0.16, above the 50-day MA of 0.15, and above the 200-day MA of 0.15, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 44.30 is Neutral, neither overbought nor oversold. The STOCH value of 29.41 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1332.
China Touyun Tech Group Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $18.38B | 12.79 | -2.54% | 3.03% | 1.52% | -15.83% | |
54 Neutral | HK$658.98M | 27.78 | 12.61% | 0.57% | 19.35% | 53.85% | |
51 Neutral | HK$905.24M | 11.81 | 1.77% | 9.21% | -28.18% | -67.44% | |
45 Neutral | HK$433.48M | 2.19 | 473.76% | ― | -39.50% | ― | |
45 Neutral | HK$841.77M | -21.09 | -7.47% | 2.86% | 3.70% | -24.49% | |
42 Neutral | HK$48.85M | 9.40 | -1.85% | ― | 50.21% | -74.97% |
* Consumer Cyclical Sector Average
HK:1332
China Touyun Tech Group
0.15
0.07
96.05%
HK:0468
Greatview Aseptic Packaging Company
2.50
0.00
0.00%
HK:0716
Singamas Container Holdings
0.38
-0.24
-38.51%
HK:1820
Pacific Millennium Packaging Group Corp.
2.80
0.58
26.07%
HK:6898
China Aluminum Cans Holdings Ltd.
0.70
-0.04
-4.76%
HK:8291
Wan Cheng Metal Packaging Company Limited
0.23
-0.04
-14.55%
China Touyun Tech Group Corporate Events
Touyun Biotech Sets Liquidity and Growth Measures to Address Going-Concern Audit Disclaimer
Sep 30, 2026
Touyun Biotech Group Limited has outlined a series of measures to address a disclaimer of opinion on its going-concern status, primarily by reinforcing its capital base and diversifying revenue sources. The group is launching new health products a...
Touyun Biotech Grants 74.6 Million Share Options to Director and Staff
Sep 24, 2026
Touyun Biotech Group Limited has granted share options under its 2025 Share Option Scheme to one executive director and 22 employees, covering a total of 74,583,800 shares. The options carry an exercise price of HK$0.20 per share, set above recent...
Touyun Biotech Raises HK$15 Million via Share Subscription to Fund New Materials Expansion
Sep 7, 2026
Touyun Biotech Group Limited has completed a share subscription under its general mandate, issuing 123,000,000 new shares at HK$0.122 each to a new subscriber, raising gross proceeds of HK$15.01 million. The new shares represent about 4.20% of the...
Touyun Biotech Details HK$15 Million Share Subscription Proceeds
Aug 31, 2026
Touyun Biotech Group Limited has clarified the planned use of proceeds from its previously announced subscription of new shares under a general mandate in Hong Kong. The gross funds raised are expected to be about HK$15 million, with net proceeds ...
Touyun Biotech Delivers Strong Interim Profit Surge on Higher Other Income
Aug 28, 2026
Touyun Biotech Group Limited reported a sharp increase in unaudited profit for the six months ended 30 June 2026, with total profit rising to HK$310.8 million from HK$28.1 million a year earlier. Earnings attributable to shareholders surged to HK$...
Touyun Biotech forecasts more than tenfold jump in first-half profit
Aug 26, 2026
Touyun Biotech Group Limited has alerted shareholders that it expects to report profit and total comprehensive income attributable to owners of between HK$180 million and HK$200 million for the six months ended 30 June 2026, compared with HK$16 mi...
Touyun Biotech to Raise HK$15 Million via Discounted Share Subscription
Aug 25, 2026
Touyun Biotech Group Limited has entered into an agreement with a subscriber to issue 123,000,000 new shares under its existing general mandate. The new shares represent about 4.38% of the current issued share capital and around 4.20% after enlarg...
Touyun Biotech Sets Board Meeting to Review Interim Results and Dividend
Aug 14, 2026
Touyun Biotech Group Limited has scheduled a board meeting for 28 August 2026 in Hong Kong to review and approve its interim results for the six months ended 30 June 2026. The session will also consider the declaration of an interim dividend, sign...
Touyun Biotech appoints new vice chairlady to lead expansion in new materials
Aug 3, 2026
Touyun Biotech Group has appointed Ms. Zhou Ruijuan as executive director and vice chairlady, effective 3 August 2026, tasking her with overseeing development of the group’s new materials business. Her appointment signals management’s ...
Touyun Biotech Clarifies Board and Committee Roles in Governance Update
Aug 3, 2026
Touyun Biotech Group Limited has announced the current composition of its board of directors, naming Wang Liang as chairman, Zhou Ruijuan as vice chairlady, and detailing the roles of its executive, non-executive and independent non-executive memb...
Touyun Biotech Shifts Registered Office in Bermuda
Aug 3, 2026
Touyun Biotech Group Limited has announced that it will change the address of its registered office in Bermuda to Richmond House, 12 Par-la-Ville Road, Hamilton HM 08, effective 3 August 2026. The move is largely administrative in nature but may r...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.